🔎︎
Phase 3 data presented at the 2026 AAN Annual Meeting by Alexion and AstraZeneca Rare Disease could reshape the treatment and site-of-care calculus for generalized myasthenia gravis (gMG), a rare autoimmune neuromuscular disorder whose current standard-of-care biologics require intravenous administration in clinical settings.
Results from the PREVAIL Phase 3 trial evaluated gefurulimab, a novel dual-binding nanobody, as a self-administered, once-weekly subcutaneous treatment option for adults with anti-acetylcholine receptor antibody-positive gMG. The trial met statistical significance on its secondary endpoint of change in the Myasthenia Gravis Composite score at Week 26, with a treatment difference of -3.1 versus placebo (P<0.0001), building on data previously presented at the 2025 Myasthenia Gravis Foundation of America scientific session.
The distinction that carries the most weight for managed care is the delivery mechanism. The approved complement inhibitors currently used in gMG, eculizumab and ravulizumab, are administered intravenously at infusion centers, generating significant medical benefit expenditures beyond the drug cost itself. A self-administered subcutaneous nanobody, if approved, would shift gMG treatment toward the pharmacy benefit and reduce the site-of-care overhead that currently drives a substantial share of per-patient spend in this population.
Myasthenia gravis affects an estimated 36,000 to 60,000 individuals in the United States, with prevalence rising as awareness and diagnostic sensitivity improve. For plans managing members on existing complement inhibitors, gefurulimab represents a potential lower-cost, lower-logistics alternative that may warrant a preferred tier position should it receive regulatory approval. Alexion has not yet announced an NDA timeline, but the PREVAIL data position the compound for a regulatory submission discussion in the near term.
